1. Home
  2. BR vs DGX Comparison

BR vs DGX Comparison

Compare BR & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Broadridge Financial Solutions Inc.

BR

Broadridge Financial Solutions Inc.

HOLD

Current Price

$184.66

Market Cap

26.1B

ML Signal

HOLD

Logo Quest Diagnostics Incorporated

DGX

Quest Diagnostics Incorporated

HOLD

Current Price

$211.68

Market Cap

23.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BR
DGX
Founded
1962
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.1B
23.1B
IPO Year
2006
1996

Fundamental Metrics

Financial Performance
Metric
BR
DGX
Price
$184.66
$211.68
Analyst Decision
Buy
Buy
Analyst Count
6
13
Target Price
$246.17
$208.62
AVG Volume (30 Days)
1.6M
1.0M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
2.13%
1.63%
EPS Growth
21.16
13.78
EPS
3.82
8.75
Revenue
$4,142,600,000.00
$11,035,000,000.00
Revenue This Year
$10.09
$7.09
Revenue Next Year
$4.32
$3.70
P/E Ratio
$48.18
$32.09
Revenue Growth
N/A
11.78
52 Week Low
$163.71
$157.20
52 Week High
$271.91
$213.20

Technical Indicators

Market Signals
Indicator
BR
DGX
Relative Strength Index (RSI) 46.34 71.50
Support Level $163.71 $177.52
Resistance Level $229.53 $213.20
Average True Range (ATR) 5.12 5.50
MACD 2.25 0.50
Stochastic Oscillator 94.57 93.06

Price Performance

Historical Comparison
BR
DGX

About BR Broadridge Financial Solutions Inc.

Broadridge Financial Solutions, which was spun off from Automatic Data Processing in 2007, is a leading provider of investor communication and technology-driven solutions to banks, broker/dealers, traditional and alternative-asset managers, wealth managers, and corporate issuers. Broadridge is composed of two operating segments: investor communication solutions and global technology and operations.

About DGX Quest Diagnostics Incorporated

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Share on Social Networks: